Table 4.
Subgroup analysis of CTA expression in variable pathological types
| Variables | SCC
|
ADC
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis
|
Multivariate analysis
|
Univariate analysis
|
Multivariate analysis
|
|||||||||
| O/N | % | P | 95% CI | HR | P | O/N | % | P | 95% CI | HR | P | |
| Sex | 0.447 | 0.291 | ||||||||||
| Male | 39/90 | 43.3 | 20/42 | 47.6 | ||||||||
| Female | 3/10 | 30.0 | 22/58 | 37.9 | ||||||||
| Age (years) | 0.203 | 0.144 | 1.010–4.398 | 2.107 | 0.047 | |||||||
| <65 | 32/81 | 39.5 | 32/82 | 39.0 | ||||||||
| ≥65 | 10/19 | 52.6 | 10/18 | 55.6 | ||||||||
| Smoking history | 0.689 | 0.898 | ||||||||||
| No | 6/15 | 40.0 | 26/62 | 41.9 | ||||||||
| Yes | 36/85 | 42.4 | 16/38 | 42.1 | ||||||||
| Chemotherapy | 0.008 | 0.183–0.678 | 0.352 | 0.002 | 0.526 | |||||||
| No | 26/48 | 54.2 | 22/48 | 45.8 | ||||||||
| Yes | 16/52 | 30.8 | 20/52 | 38.5 | ||||||||
| Thoracic radiotherapy | 0.466 | 0.188 | 0.076–1.349 | 0.321 | 0.121 | |||||||
| No | 38/88 | 43.2 | 40/88 | 45.5 | ||||||||
| Yes | 4/12 | 33.3 | 2/12 | 16.7 | ||||||||
| TNM stage | 0.226 | 0.088 | 1.094–4.408 | 2.196 | 0.027 | |||||||
| IIIA | 30/75 | 40.0 | 30/78 | 38.5 | ||||||||
| IIIB | 12/25 | 48.0 | 12/22 | 54.6 | ||||||||
| MAGEA1 | 0.421 | 0.726 | ||||||||||
| Negative | 15/44 | 34.1 | 14/36 | 38.9 | ||||||||
| Positive | 27/56 | 48.2 | 28/64 | 43.8 | ||||||||
| MAGEA3 | 0.834 | 0.834 | ||||||||||
| Negative | 34/87 | 39.1 | 28/66 | 42.4 | ||||||||
| Positive | 8/17 | 47.1 | 14/34 | 41.2 | ||||||||
| MAGEA10 | 0.916 | 0.072 | 0.287–0.979 | 0.530 | 0.043 | |||||||
| Negative | 26/61 | 42.6 | 20/39 | 51.3 | ||||||||
| Positive | 16/39 | 41.0 | 22/61 | 36.1 | ||||||||
| MAGEB2 | 0.526 | 0.497 | ||||||||||
| Negative | 26/58 | 44.8 | 33/73 | 45.2 | ||||||||
| Positive | 16/42 | 38.1 | 9/27 | 33.3 | ||||||||
| MAGEC1 | 0.484 | 0.389 | ||||||||||
| Negative | 29/70 | 41.4 | 17/37 | 46.0 | ||||||||
| Positive | 13/30 | 43.3 | 25/63 | 39.7 | ||||||||
| XAGE1 | 0.120 | 0.238–1.224 | 0.539 | 0.140 | 0.464 | |||||||
| Negative | 35/76 | 46.1 | 24/51 | 47.1 | ||||||||
| Positive | 7/24 | 29.2 | 18/49 | 36.7 | ||||||||
| KK-LC-1 | 0.263 | 0.712 | ||||||||||
| Negative | 18/53 | 34.0 | 21/52 | 40.1 | ||||||||
| Positive | 24/47 | 51.1 | 21/48 | 43.8 | ||||||||
| CTAG1A/B | 0.482 | 0.752 | ||||||||||
| Negative | 31/80 | 38.8 | 21/50 | 42.0 | ||||||||
| Positive | 11/20 | 55.0 | 21/50 | 42.0 | ||||||||
| VCX1 | 0.087 | 1.138–4.132 | 2.168 | 0.019 | 0.464 | |||||||
| Negative | 25/71 | 35.2 | 34/76 | 44.7 | ||||||||
| Positive | 17/29 | 58.6 | 8/24 | 33.3 | ||||||||
| VCX3A | 0.264 | 0.324 | ||||||||||
| Negative | 32/70 | 45.7 | 31/76 | 40.8 | ||||||||
| Positive | 10/30 | 33.3 | 11/24 | 45.8 | ||||||||
Note: Only factors with a P-value <0.05 are labeled as bolded numbers.
Abbreviations: CTA, cancer/testis antigen; SCC, squamous cell carcinoma; ADC, adenocarcinoma; CI, confidence interval; HR, hazard ratio; O/N, observed death number/total patient number in each group.